PharmaTher Holdings Ltd. (CSE: PHRM; OTCQB: PHRRF) is a Toronto-based life sciences company focused on personalized medicines and pharmaceutical 3D-printing technologies. The Canadian Securities Exchange lists 91,019,065 shares issued and outstanding. In its latest publicly available interim financial statements, the company reported C$794,804 in cash and no revenue to date as of February 28, 2026.
PharmaTher announced on August 11 that it established PERSONALIZ3D, a planned platform combining telehealth, pharmaceutical 3D printing and pharmacy fulfillment. The initiative expands the company’s previously announced Personaliz3D Peptides program to include other therapeutic categories and compounded prescriptions.
The proposed model would connect eligible patients with independent licensed healthcare providers through telehealth. Prescribed medicines could then be customized through digitally controlled 3D-printing workflows and dispensed by qualified pharmacy partners. The company said potential customization may include dose, drug combinations, release profiles and dosage forms.
PharmaTher outlined a three-stage rollout. It first plans to select a qualified U.S. Section 503A pharmacy as a Center of Excellence. The second stage would introduce a controlled telehealth-enabled commercial program, followed by an evaluation of pharmaceutical 3D-printing system placements with U.S. and Canadian compounding pharmacies.
“By connecting telehealth access, pharmacy-based production and digital traceability, we believe PERSONALIZ3D can provide a differentiated and scalable model for personalized medicines,” CEO Fabio Chianelli said.
The platform is expected to build on PharmaTher’s collaboration with Craft Health and its CraftMake pharmaceutical 3D-printing system. PharmaTher identified potential future revenue channels including telehealth services, printer placements, consumables, software access, maintenance, product development and licensing. These remain company plans: PERSONALIZ3D is still under development and has not begun commercial operations. PharmaTher has not announced a pharmacy partner, launch date, system-placement volume, pricing or revenue guidance.
The company cited the July 2026 recommendations of the U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee as part of the regulatory backdrop for selected peptides. The FDA states that advisory-committee recommendations are non-binding, and any related PharmaTher activities remain subject to applicable regulations.
PharmaTher’s interim filings reported a C$690,017 net loss for the nine months ended February 28, 2026. The company said its ability to continue as a going concern depends on raising additional capital and warned that equity financing could significantly dilute shareholders.
Upcoming Catalysts
- Company-specific: Selection of a Section 503A pharmacy partner, launch of the controlled telehealth program and any initial pharmacy-system placements.
- Regulatory: Any FDA action following the July 2026 advisory-committee recommendations concerning selected substances for the Section 503A Bulks List.
Sources
- PharmaTher establishes PERSONALIZ3D, August 11, 2026 — Newsfile Corp.
- PharmaTher Holdings Ltd. CSE issuer profile — Canadian Securities Exchange
- PharmaTher unaudited interim financial statements for the nine months ended February 28, 2026 — CSE/SEDAR filing
- July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting — U.S. FDA
Editorial Disclosure
This article is based entirely on publicly available information including press releases, SEDAR filings and publicly available regulatory and exchange sources. Securities discussed or referenced include PharmaTher Holdings Ltd. (CSE: PHRM; OTCQB: PHRRF). Biotech Stocks Daily has not received any compensation from any company mentioned, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which does not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Sources used were PharmaTher’s August 11, 2026 press release distributed through Newsfile Corp.; PharmaTher’s unaudited interim financial statements for the three and nine months ended February 28, 2026, available through CSE/SEDAR; the Canadian Securities Exchange issuer profile accessed August 12, 2026; and the FDA’s page for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting.
As of February 28, 2026, PharmaTher reported C$794,804 in cash, a C$690,017 net loss for the nine-month period and no revenue to date. Its filings identified material uncertainties that may cast significant doubt on its ability to continue as a going concern and stated that additional equity financing could significantly dilute shareholders. PERSONALIZ3D remains under development and has not commenced commercial operations. PharmaTher has not announced a pharmacy partner, commercial launch date, system-placement volume, pricing or revenue guidance for the platform.
Financial and share-count information reflects the dates stated above and may change. No market-price data was used in this article. Readers should verify current filings and market information before making decisions.
These are speculative investments carrying significant risk, including potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information, please see our full DISCLAIMER.
